NASDAQ:XBITXBiotech Stock Price, Forecast & News

XBiotech's stock was trading at $10.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, XBIT stock has increased by 30.3% and is now trading at $13.97. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XBiotech.

XBiotech is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for XBiotech.

XBiotech Inc (NASDAQ:XBIT) released its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.15). View XBiotech's earnings history.

2 brokers have issued 1-year price objectives for XBiotech's shares. Their forecasts range from $18.00 to $28.00. On average, they anticipate XBiotech's stock price to reach $23.00 in the next year. This suggests a possible upside of 64.6% from the stock's current price. View analysts' price targets for XBiotech.

Media coverage about XBIT stock has been trending very negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. XBiotech earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about XBiotech.

Some companies that are related to XBiotech include Intercept Pharmaceuticals (ICPT), Mersana Therapeutics (MRSN), BELLUS Health (BLUSF), Kiniksa Pharmaceuticals (KNSA), Zogenix (ZGNX), Revance Therapeutics (RVNC), Amneal Pharmaceuticals (AMRX), Esperion Therapeutics (ESPR), Innoviva (INVA), Portola Pharmaceuticals (PTLA), Cytokinetics (CYTK), ZEALAND PHARMA/S (ZEAL), Karyopharm Therapeutics (KPTI), Akcea Therapeutics (AKCA) and Tricida (TCDA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Cidara Therapeutics (CDTX), Micron Technology (MU), Novavax (NVAX), Ocular Therapeutix (OCUL), Sanofi (SNY), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

(XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XBIT stock can currently be purchased for approximately $13.97.

XBiotech has a market capitalization of $403.03 million. The biopharmaceutical company earns $668.63 million in net income (profit) each year or ($0.68) on an earnings per share basis. XBiotech employs 56 workers across the globe.

The official website for XBiotech is www.xbiotech.com.

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]